Marteka Deli, Malik Amarila, Faustine Ingrid, Syafhan Nadia Farhanah
Graduate Program, Division of Clinical Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia.
Lahat Regional General Hospital (Rumah Sakit Umum Daerah Lahat), Lahat 31461, South Sumatera, Indonesia.
Belitung Nurs J. 2022 Dec 27;8(6):529-537. doi: 10.33546/bnj.2302. eCollection 2022.
Although there are fewer COVID-19 cases in Indonesia, the pandemic is still ongoing. COVID-19 has a significant death rate in Indonesia, but lack of information on the effect of different clinical and demographic factors on COVID-19-related grimness and mortality in Indonesia.
This study examined the clinical profile, treatment, and outcomes of patients with COVID-19 at Lahat Regency Hospital in South Sumatera, Indonesia, to find relevant markers that might be utilized to predict the prognosis of these patients.
This was a retrospective single-center study of all medical record files of confirmed patients with COVID-19 admitted to Lahat Hospital from September 2020 to August 2021 ( = 285). Descriptive statistics, Chi-square, Mann-Whitney, Multiple Logistic Regression, and Cox's proportional hazards model were used for data analyses.
This study included 65 non-hospitalized and 220 hospitalized patients. Hospitalized patients were divided into dead and alive groups. The median age was lower in the non-hospitalized group without gender discrimination, and most hospitalized patients had comorbidities. Vital signs and clinical features were significantly different in hospitalized patients compared to non-hospitalized. The survival patients in the hospitalized group showed lower white blood cell (WBC), neutrophil percentages, and neutrophil-lymphocyte ratio (NLR) but higher lymphocyte and eosinophil. Non-survival patients had elevated alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine, blood glucose, and potassium. The use of Favipiravir and Remdesivir was significant between the alive and dead groups. The mean hospital stay for all patients was 9.49 ± 4.77 days, while the median duration of hospital time was 10.73 ± 4.33 days in the survival group and 5.39 ± 3.78 days in the non-survival group. Multiple logistic regression analysis determined respiration rate, WBC, and BUN as predictors of survival.
Age and comorbidities are significant elements impacting the seriousness of COVID-19. Abnormal signs in laboratory markers can be used as early warning and prognostic signs to prevent severity and death. Potential biomarkers at various degrees in patients with COVID-19 may also aid healthcare professionals in providing precision medicine and nursing.
尽管印度尼西亚的新冠病毒病（COVID-19）病例较少，但疫情仍在持续。在印度尼西亚，COVID-19的死亡率较高，但缺乏关于不同临床和人口统计学因素对印度尼西亚COVID-19相关严重程度和死亡率影响的信息。
本研究调查了印度尼西亚南苏门答腊省拉哈特摄政医院COVID-19患者的临床特征、治疗情况及预后，以寻找可能用于预测这些患者预后的相关指标。
这是一项对2020年9月至2021年8月期间入住拉哈特医院的确诊COVID-19患者的所有病历档案进行的回顾性单中心研究（n = 285）。采用描述性统计、卡方检验、曼-惠特尼检验、多元逻辑回归和Cox比例风险模型进行数据分析。
本研究纳入了65例非住院患者和220例住院患者。住院患者分为死亡组和存活组。非住院组的中位年龄较低，无性别差异，大多数住院患者患有合并症。与非住院患者相比，住院患者的生命体征和临床特征有显著差异。住院组存活患者的白细胞（WBC）、中性粒细胞百分比和中性粒细胞-淋巴细胞比值（NLR）较低，但淋巴细胞和嗜酸性粒细胞较高。非存活患者的丙氨酸转氨酶（ALT）、血尿素氮（BUN）、肌酐、血糖和钾升高。法匹拉韦和瑞德西韦在存活组和死亡组之间的使用有显著差异。所有患者的平均住院时间为9.49±4.77天，而存活组的中位住院时间为10.73±4.3天，非存活组为5.39±3.78天。多元逻辑回归分析确定呼吸频率、WBC和BUN为存活的预测因素。
年龄和合并症是影响COVID-19严重程度的重要因素。实验室指标异常可作为预警和预后指标，以预防病情严重和死亡。COVID-19患者不同程度的潜在生物标志物也可能有助于医护人员提供精准医疗和护理。
